Rufinamide
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lennox Gastaut Syndrome
Conditions
Lennox Gastaut Syndrome
Trial Timeline
— → —
NCT ID
NCT03778424About Rufinamide
Rufinamide is a pre-clinical stage product being developed by Eisai for Lennox Gastaut Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT03778424. Target conditions include Lennox Gastaut Syndrome.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03778424 | Pre-clinical | Active |
| NCT02175173 | Pre-clinical | Completed |
| NCT01151540 | Phase 3 | Completed |
| NCT00448539 | Phase 3 | Terminated |
Competing Products
11 competing products in Lennox Gastaut Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + Perampanel | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide (E2080) + Placebo | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Rufinamide + Any other approved Antiepileptic Drug | Eisai | Phase 3 | 77 |
| ZX008 0.2 or 0.8 mg/kg/day + Matching Placebo | UCB | Phase 3 | 74 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Pre-clinical | 20 |
| Cannabidiol | Jazz Pharmaceuticals | Approved | 82 |
| GWP42003-P | Jazz Pharmaceuticals | Approved | 82 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 72 |